|
|
 |
Trial Information
Summary: A Clinical Research Study for Adults with Moderately-to Severely-Active Crohn’s Disease
This study is testing an investigational medication for the
treatment of Crohn's disease in 100 volunteers across the US
and Canada. Each participant will be randomly assigned to 1 of
several doses of the study drug, or to placebo (1 in 3 chance).
If you are eligible for this study and decide to participate,
all study medications, study-related medical examinations, and
laboratory tests will be provided to you at no cost.
You will be asked to:
- Attend about 6 clinic visits, 6 short urine collection visits,
and stay in touch with clinic staff over a period of 4 months.
Certain clinic visits include collecting blood, urine or stool
samples, a complete physical exam, medical history review, and
completing health related questionnaires.
- Follow all instructions of the doctor and study staff,
including taking your study medication on time and coming to your
scheduled appointments. You are also responsible for sharing your
concerns and questions with the study doctor and staff.
- Use an approved method of birth control and have pregnancy
testing completed during the study if you are a woman of
childbearing potential.
You may be eligible to participate in this study if
you:
- Are currently experiencing an active flare up of Crohn's
Disease.
- Are 18 to 65 years of age.
- Study staff will review other criteria at the first
visit.
|
Contact:
Veronica Yung or Marcela Merchan
Gastroenterology Research Associates, LLC
65 Ridgedale Avenue
Cedar Knolls, NJ 07927
Telephone: 973-401-0500 ext 101 or 111
|
|

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.
Trial listings updated: June 1, 2008 at 6:31:40 AM
|
 |
|